Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.43 |
| ▸ | CA1 | P00915 | 9/20 | 0.43 |
| ▸ | CA12 | O43570 | 7/20 | 0.43 |
| ▸ | CA9 | Q16790 | 7/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16845423 | 1.00 | CA2 (0.43) | CA2CA1CA12CA9KDR | |
| SCHEMBL20707879 | 0.88 | KDR (0.41) | KDRBRAFSLC9A1 | |
| SCHEMBL16845374 | 0.86 | KDR (0.42) | KDRBRAFSLC9A1 | |
| SCHEMBL16820015 | 0.86 | KDR (0.42) | KDRBRAFSLC9A1 | |
| SCHEMBL16845461 | 0.83 | RORC (0.38) | CA2CA1CA12CA9CA7 | |
| SCHEMBL16820010 | 0.83 | RORC (0.38) | CA2CA1CA12CA9CA7 | |
| SCHEMBL18919095 | 0.81 | CA1 (0.54) | CA2CA1CA12CA9CA7 | |
| SCHEMBL16845445 | 0.80 | CA2 (0.44) | CA2CA1CA12CA9PTGS1 | |
| SCHEMBL18919029 | 0.80 | CA2 (0.44) | CA2CA1CA12CA9PTGS1 | |
| SCHEMBL16819975 | 0.80 | CA2 (0.44) | CA2CA1CA12CA9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888229-B1 | alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-02-06 | — | — | EP | disclosed |
| US-9790173-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME CORP. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | CHRNA7, CHRNA5, CHRNA6 | CA2 2747/4885CA1 1704/4885CA12 3185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.